Symbiotec Pharmalab Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Low debt relative to equity (D/E 0.3x)
Concerns
- Trading near 52-week high (₹1,310)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Latest News
All newsSymbiotec Pharmalab's US FDA inspection yields VAI classification
*Symbiotac Pharmalab receives VAI classification from US FDA after inspection.* The Establishment Inspection Report (EIR) for its Pithampur SEZ facility indicates observations requiring corrective actions. **VAI** means Voluntary Action Indicated, potentially delaying US market expansion. Regulatory compliance focus intensifies near-term operational risks. 📊 *STOCKS:* $SYMBIOTEC | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Symbiotec Pharmalab hosts investor meet with updates
*Symbiotec Pharmalab hosts investor meet with updates* on business performance and strategy. The company shared insights during its analyst and institutional investor call, with a recording made available. No financial figures or major announcements were disclosed. The event aimed to enhance investor engagement and transparency. 📊 *STOCKS:* $SYMBIOTEC | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Symbiotec Pharmalab publishes notice in newspaper
*Symbiotec Pharmalab publishes notice in newspaper* as part of regulatory compliance. The filing is a routine copy of newspaper publication, likely related to annual general meeting or board meeting intimation. No financial or operational update was disclosed. Such notices are standard under listing obligations. 📊 *STOCKS:* SYMBIOTEC | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Symbiotec Pharmalab shares update under SEBI insider trading norms
Symbiotec Pharmalab filed an update under SEBI's insider trading regulations. The disclosure follows Regulation 8(2) of the Prohibition of Insider Trading norms. No material financial or operational details were revealed. This is a routine compliance filing. 📊 *STOCKS:* $SYMBIOTEC | 🏢 *SECTOR:* Pharma | #LOWIMPACT #SEBI
Financials
Quarterly Results
| Metric | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | ₹218 Cr 11.0% | ₹245 Cr 20.7% | ₹203 Cr |
| Op. Profit | ₹45 Cr 27.4% | ₹62 Cr 6.9% | ₹58 Cr |
| OPM | 21.0% 16.0% | 25.0% 13.8% | 29.0% |
| Net Profit | ₹14 Cr 50.0% | ₹28 Cr 6.7% | ₹30 Cr |
| EPS (₹) | 2.24 49.0% | 4.39 90.7% | 46.99 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue | ₹869 Cr 15.6% | ₹752 Cr 5.0% | ₹716 Cr 26.3% | ₹567 Cr 16.9% | ₹682 Cr 7.7% | ₹633 Cr |
| Expenses | ₹630 Cr 14.8% | ₹549 Cr 0.9% | ₹544 Cr 9.5% | ₹497 Cr 9.6% | ₹550 Cr 25.6% | ₹438 Cr |
| Op. Profit | ₹239 Cr 17.7% | ₹203 Cr 18.0% | ₹172 Cr 145.7% | ₹70 Cr 46.6% | ₹131 Cr 32.8% | ₹195 Cr |
| OPM | 27.0% 0.0% | 27.0% 12.5% | 24.0% 100.0% | 12.0% 36.8% | 19.0% 38.7% | 31.0% |
| Other Income | ₹-6 Cr 250.0% | ₹4 Cr 42.9% | ₹7 Cr 16.7% | ₹6 Cr 100.0% | ₹3 Cr 57.1% | ₹7 Cr |
| Interest | ₹26 Cr 52.9% | ₹17 Cr 112.5% | ₹8 Cr 0.0% | ₹8 Cr 166.7% | ₹3 Cr 57.1% | ₹7 Cr |
| Depreciation | ₹53 Cr 23.3% | ₹43 Cr 10.3% | ₹39 Cr 34.5% | ₹29 Cr 11.5% | ₹26 Cr 18.2% | ₹22 Cr |
| PBT | ₹153 Cr 4.1% | ₹147 Cr 11.4% | ₹132 Cr 238.5% | ₹39 Cr 62.9% | ₹105 Cr 39.3% | ₹173 Cr |
| Tax % | 28.0% 17.6% | 34.0% 47.8% | 23.0% 39.5% | 38.0% 40.7% | 27.0% 3.6% | 28.0% |
| Net Profit | ₹110 Cr 13.4% | ₹97 Cr 3.0% | ₹100 Cr 334.8% | ₹23 Cr 70.5% | ₹78 Cr 36.6% | ₹123 Cr |
| EPS (₹) | 17.51 88.5% | 151.98 730.9% | 18.29 326.3% | 4.29 69.7% | 14.17 37.1% | 22.54 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Liabilities | ||||||
| Equity Capital | ₹13 Cr 18.2% | ₹11 Cr 0.0% | ₹11 Cr 0.0% | ₹11 Cr 0.0% | ₹11 Cr 0.0% | ₹11 Cr |
| Reserves | ₹1.1K Cr 41.4% | ₹804 Cr 14.2% | ₹704 Cr 15.2% | ₹611 Cr 3.9% | ₹588 Cr 15.3% | ₹510 Cr |
| Borrowings | ₹391 Cr 28.1% | ₹544 Cr 120.2% | ₹247 Cr 13.3% | ₹218 Cr 235.4% | ₹65 Cr 38.3% | ₹47 Cr |
| Other Liabilities | ₹240 Cr 9.1% | ₹220 Cr 32.5% | ₹326 Cr 115.9% | ₹151 Cr 0.7% | ₹152 Cr 24.0% | ₹200 Cr |
| Total Liabilities | ₹1.8K Cr 12.7% | ₹1.6K Cr 22.6% | ₹1.3K Cr 30.2% | ₹990 Cr 21.5% | ₹815 Cr 6.1% | ₹768 Cr |
Assets | ||||||
| Fixed Assets | ₹1.1K Cr 155.7% | ₹438 Cr 2.2% | ₹448 Cr 49.8% | ₹299 Cr 6.8% | ₹280 Cr 7.3% | ₹261 Cr |
| CWIP | ₹64 Cr 88.7% | ₹568 Cr 173.1% | ₹208 Cr 14.3% | ₹182 Cr 355.0% | ₹40 Cr 42.9% | ₹28 Cr |
| Investments | ₹4 Cr 300.0% | ₹1 Cr 75.0% | ₹4 Cr 20.0% | ₹5 Cr 0.0% | ₹5 Cr 0.0% | ₹5 Cr |
| Other Assets | ₹592 Cr 3.5% | ₹572 Cr 8.9% | ₹628 Cr 24.6% | ₹504 Cr 2.9% | ₹490 Cr 3.4% | ₹474 Cr |
| Total Assets | ₹1.8K Cr 12.7% | ₹1.6K Cr 22.6% | ₹1.3K Cr 30.2% | ₹990 Cr 21.5% | ₹815 Cr 6.1% | ₹768 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Operating CF | ₹175 Cr 272.3% | ₹47 Cr 75.0% | ₹188 Cr 172.5% | ₹69 Cr 283.3% | ₹18 Cr 89.7% | ₹174 Cr |
| Investing CF | ₹-227 Cr 26.1% | ₹-307 Cr 49.0% | ₹-206 Cr 6.4% | ₹-220 Cr 587.5% | ₹-32 Cr 66.7% | ₹-96 Cr |
| Financing CF | ₹36 Cr 87.1% | ₹278 Cr 1163.6% | ₹22 Cr 84.9% | ₹146 Cr 873.3% | ₹15 Cr 119.0% | ₹-79 Cr |
| Net Cash Flow | ₹-16 Cr 184.2% | ₹19 Cr 533.3% | ₹3 Cr 160.0% | ₹-5 Cr 600.0% | ₹1 Cr 200.0% | ₹-1 Cr |
| Free Cash Flow | ₹-50 Cr 80.8% | ₹-261 Cr 1086.4% | ₹-22 Cr 85.8% | ₹-155 Cr 181.8% | ₹-55 Cr 163.2% | ₹87 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 83d 2.4% | 85d 32.8% | 64d 11.1% | 72d 6.5% | 77d 13.2% | 68d |
| Inventory Days | 274d 14.6% | 321d 16.0% | 382d 25.2% | 305d 21.0% | 252d 18.2% | 308d |
| Days Payable | 160d 46.8% | 109d 57.9% | 259d 135.5% | 110d 20.9% | 91d 41.3% | 155d |
| Cash Conv. Cycle | 197d 33.9% | 298d 59.4% | 187d 30.0% | 267d 12.2% | 238d 7.7% | 221d |
| Working Capital Days | -22d 633.3% | -3d 103.9% | 76d 29.0% | 107d 11.6% | 121d 40.7% | 86d |
| ROCE | 13.0% 7.1% | 14.0% 12.5% | 16.0% 166.7% | 6.0% 66.7% | 18.0% | — |
Source: Screener.in · Lower days = better efficiency